{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:30:19Z","timestamp":1789140619210,"version":"build-2803163510"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T00:00:00Z","timestamp":1739059200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T00:00:00Z","timestamp":1739059200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2022RC080, 2024KY1728, and 2024KY1709"],"award-info":[{"award-number":["2022RC080, 2024KY1728, and 2024KY1709"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2022RC080, 2024KY1728, and 2024KY1709"],"award-info":[{"award-number":["2022RC080, 2024KY1728, and 2024KY1709"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2022RC080, 2024KY1728, and 2024KY1709"],"award-info":[{"award-number":["2022RC080, 2024KY1728, and 2024KY1709"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shaoxing Health Science and Technology Project","award":["2022SY011"],"award-info":[{"award-number":["2022SY011"]}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LY22H160008"],"award-info":[{"award-number":["LY22H160008"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-89423-0","type":"journal-article","created":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T00:13:46Z","timestamp":1739060026000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Establishment and characterization of three gemcitabine-resistant human intrahepatic cholangiocarcinoma cell lines"],"prefix":"10.1038","volume":"15","author":[{"given":"Jiandong","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanxin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiguang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baochun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,9]]},"reference":[{"key":"89423_CR1","doi-asserted-by":"publisher","first-page":"107327482110515","DOI":"10.1177\/10732748211051548","volume":"29","author":"J Yao","year":"2022","unstructured":"Yao, J., Liang, X., Liu, Y., Li, S. & Zheng, M. Trends in incidence and prognostic factors of two subtypes of primary liver cancers: a Surveillance, Epidemiology, and end results-based Population Study. Cancer Control. 29, 10732748211051548. https:\/\/doi.org\/10.1177\/10732748211051548 (2022).","journal-title":"Cancer Control"},{"key":"89423_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"89423_CR3","doi-asserted-by":"publisher","first-page":"977111","DOI":"10.3389\/fonc.2022.977111","volume":"12","author":"G Deng","year":"2022","unstructured":"Deng, G. et al. Tumor burden score dictates prognosis of patients with combined hepatocellular cholangiocarcinoma undergoing hepatectomy. Front. Oncol. 12, 977111. https:\/\/doi.org\/10.3389\/fonc.2022.977111 (2022).","journal-title":"Front. Oncol."},{"key":"89423_CR4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41572-021-00300-2","volume":"7","author":"PJ Brindley","year":"2021","unstructured":"Brindley, P. J. et al. Cholangiocarcinoma. Nat. Rev. Dis. Primers. 7, 65. https:\/\/doi.org\/10.1038\/s41572-021-00300-2 (2021).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"89423_CR5","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","volume":"7","author":"AX Zhu","year":"2021","unstructured":"Zhu, A. X. et al. Final overall survival efficacy results of Ivosidenib for patients with Advanced Cholangiocarcinoma with IDH1 mutation: the phase 3 Randomized Clinical ClarIDHy Trial. JAMA Oncol. 7, 1669\u20131677. https:\/\/doi.org\/10.1001\/jamaoncol.2021.3836 (2021).","journal-title":"JAMA Oncol."},{"key":"89423_CR6","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12943-021-01482-9","volume":"21","author":"J Du","year":"2022","unstructured":"Du, J. et al. CircNFIB inhibits tumor growth and metastasis through suppressing MEK1\/ERK signaling in intrahepatic cholangiocarcinoma. Mol. Cancer. 21, 18. https:\/\/doi.org\/10.1186\/s12943-021-01482-9 (2022).","journal-title":"Mol. Cancer"},{"key":"89423_CR7","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s40425-019-0692-z","volume":"7","author":"X Liu","year":"2019","unstructured":"Liu, X. et al. Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade. J. Immunother Cancer. 7, 204. https:\/\/doi.org\/10.1186\/s40425-019-0692-z (2019).","journal-title":"J. Immunother Cancer"},{"key":"89423_CR8","doi-asserted-by":"publisher","unstructured":"Wang, C. et al. Specific risk factors contributing to early and late recurrences of intrahepatic cholangiocarcinoma after curative resection. World J. Surg. Oncol. 17 https:\/\/doi.org\/10.1186\/s12957-018-1540-1 (2019).","DOI":"10.1186\/s12957-018-1540-1"},{"key":"89423_CR9","doi-asserted-by":"publisher","unstructured":"Doussot, A. et al. Recurrence patterns and Disease-Free Survival after Resection of Intrahepatic Cholangiocarcinoma: preoperative and postoperative prognostic models. J. Am. Coll. Surg. 223 https:\/\/doi.org\/10.1016\/j.jamcollsurg.2016.05.019 (2016).","DOI":"10.1016\/j.jamcollsurg.2016.05.019"},{"key":"89423_CR10","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle, J. et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl. J. Med. 362, 1273\u20131281. https:\/\/doi.org\/10.1056\/NEJMoa0908721 (2010).","journal-title":"N Engl. J. Med."},{"key":"89423_CR11","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1093\/annonc\/mdz402","volume":"30","author":"C Morizane","year":"2019","unstructured":"Morizane, C. et al. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced\/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. Ann. Oncol. 30, 1950\u20131958. https:\/\/doi.org\/10.1093\/annonc\/mdz402 (2019).","journal-title":"Ann. Oncol."},{"key":"89423_CR12","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.bbadis.2017.06.005","volume":"1864","author":"JJG Marin","year":"2018","unstructured":"Marin, J. J. G. et al. Chemoresistance and chemosensitization in cholangiocarcinoma. Biochim. Biophys. Acta Mol. Basis Dis. 1864, 1444\u20131453. https:\/\/doi.org\/10.1016\/j.bbadis.2017.06.005 (2018).","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"issue":"Suppl 5","key":"89423_CR13","doi-asserted-by":"publisher","first-page":"v7","DOI":"10.1093\/annonc\/mdj941","volume":"17","author":"E Mini","year":"2006","unstructured":"Mini, E., Nobili, S., Caciagli, B., Landini, I. & Mazzei, T. Cellular pharmacology of gemcitabine. Ann. Oncol. 17 (Suppl 5), v7\u201312 (2006).","journal-title":"Ann. Oncol."},{"key":"89423_CR14","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1093\/neuonc\/noab015","volume":"23","author":"M Yamamoto","year":"2021","unstructured":"Yamamoto, M. et al. Roles for hENT1 and dCK in gemcitabine sensitivity and malignancy of meningioma. Neuro Oncol. 23, 945\u2013954. https:\/\/doi.org\/10.1093\/neuonc\/noab015 (2021).","journal-title":"Neuro Oncol."},{"key":"89423_CR15","doi-asserted-by":"publisher","first-page":"e12456","DOI":"10.1111\/cpr.12456","volume":"51","author":"Q Hu","year":"2018","unstructured":"Hu, Q. et al. dCK negatively regulates the NRF2\/ARE axis and ROS production in pancreatic cancer. Cell. Prolif. 51, e12456. https:\/\/doi.org\/10.1111\/cpr.12456 (2018).","journal-title":"Cell. Prolif."},{"key":"89423_CR16","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.drup.2015.10.002","volume":"23","author":"Y Binenbaum","year":"2015","unstructured":"Binenbaum, Y., Na\u2019ara, S. & Gil, Z. Gemcitabine resistance in pancreatic ductal adenocarcinoma. Drug Resist. Updat. 23, 55\u201368. https:\/\/doi.org\/10.1016\/j.drup.2015.10.002 (2015).","journal-title":"Drug Resist. Updat"},{"key":"89423_CR17","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/S1470-2045(10)70244-8","volume":"12","author":"LP Jordheim","year":"2011","unstructured":"Jordheim, L. P., S\u00e8ve, P., Tr\u00e9dan, O. & Dumontet, C. The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer. Lancet Oncol. 12, 693\u2013702. https:\/\/doi.org\/10.1016\/S1470-2045(10)70244-8 (2011).","journal-title":"Lancet Oncol."},{"key":"89423_CR18","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jbior.2017.11.007","volume":"68","author":"A Adamska","year":"2018","unstructured":"Adamska, A. et al. Molecular and cellular mechanisms of chemoresistance in pancreatic cancer. Adv. Biol. Regul. 68, 77\u201387. https:\/\/doi.org\/10.1016\/j.jbior.2017.11.007 (2018).","journal-title":"Adv. Biol. Regul."},{"key":"89423_CR19","first-page":"6110","volume":"51","author":"P Huang","year":"1991","unstructured":"Huang, P., Chubb, S., Hertel, L. W., Grindey, G. B. & Plunkett, W. Action of 2\u2019,2\u2019-difluorodeoxycytidine on DNA synthesis. Cancer Res. 51, 6110\u20136117 (1991).","journal-title":"Cancer Res."},{"key":"89423_CR20","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1158\/1535-7163.MCT-06-0633","volume":"6","author":"B Ewald","year":"2007","unstructured":"Ewald, B., Sampath, D. & Plunkett, W. H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation. Mol. Cancer Ther. 6, 1239\u20131248 (2007).","journal-title":"Mol. Cancer Ther."},{"key":"89423_CR21","doi-asserted-by":"publisher","unstructured":"Saiki, Y. et al. DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells. Biochem. Biophys. Res. Commun. 421 https:\/\/doi.org\/10.1016\/j.bbrc.2012.03.122 (2012).","DOI":"10.1016\/j.bbrc.2012.03.122"},{"key":"89423_CR22","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.bbrc.2010.11.130","volume":"405","author":"H Yoon","year":"2011","unstructured":"Yoon, H., Min, J. K., Lee, J. W., Kim, D. G. & Hong, H. J. Acquisition of chemoresistance in intrahepatic cholangiocarcinoma cells by activation of AKT and extracellular signal-regulated kinase (ERK)1\/2. Biochem. Biophys. Res. Commun. 405, 333\u2013337. https:\/\/doi.org\/10.1016\/j.bbrc.2010.11.130 (2011).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"89423_CR23","doi-asserted-by":"publisher","unstructured":"Leelawat, K., Narong, S., Udomchaiprasertkul, W., Leelawat, S. & Tungpradubkul, S. Inhibition of PI3K increases oxaliplatin sensitivity in cholangiocarcinoma cells. Cancer Cell. Int. 9 (3). https:\/\/doi.org\/10.1186\/1475-2867-9-3 (2009).","DOI":"10.1186\/1475-2867-9-3"},{"key":"89423_CR24","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1016\/j.ejca.2012.12.002","volume":"49","author":"D Yamada","year":"2013","unstructured":"Yamada, D. et al. Role of crosstalk between interleukin-6 and transforming growth factor-beta 1 in epithelial-mesenchymal transition and chemoresistance in biliary tract cancer. Eur. J. Cancer. 49, 1725\u20131740. https:\/\/doi.org\/10.1016\/j.ejca.2012.12.002 (2013).","journal-title":"Eur. J. Cancer"},{"key":"89423_CR25","doi-asserted-by":"publisher","unstructured":"Krishnaraj, J., Yamamoto, T. & Ohki, R. p53-Dependent cytoprotective mechanisms behind resistance to Chemo-Radiotherapeutic agents used in Cancer Treatment. Cancers (Basel). 15 https:\/\/doi.org\/10.3390\/cancers15133399 (2023).","DOI":"10.3390\/cancers15133399"},{"key":"89423_CR26","doi-asserted-by":"publisher","first-page":"877","DOI":"10.2353\/ajpath.2006.050464","volume":"169","author":"D Alvaro","year":"2006","unstructured":"Alvaro, D. et al. Estrogens and insulin-like growth factor 1 modulate neoplastic cell growth in human cholangiocarcinoma. Am. J. Pathol. 169, 877\u2013888 (2006).","journal-title":"Am. J. Pathol."},{"key":"89423_CR27","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41568-021-00435-0","volume":"22","author":"EC Cheung","year":"2022","unstructured":"Cheung, E. C. & Vousden, K. H. The role of ROS in tumour development and progression. Nat. Rev. Cancer. 22, 280\u2013297. https:\/\/doi.org\/10.1038\/s41568-021-00435-0 (2022).","journal-title":"Nat. Rev. Cancer"},{"key":"89423_CR28","doi-asserted-by":"publisher","unstructured":"Prasad, S., Gupta, S. C. & Tyagi, A. K. Reactive oxygen species (ROS) and cancer: role of antioxidative nutraceuticals. Cancer Lett. 387 https:\/\/doi.org\/10.1016\/j.canlet.2016.03.042 (2017).","DOI":"10.1016\/j.canlet.2016.03.042"},{"key":"89423_CR29","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.freeradbiomed.2018.08.038","volume":"132","author":"JA Bolduc","year":"2019","unstructured":"Bolduc, J. A., Collins, J. A. & Loeser, R. F. Reactive oxygen species, aging and articular cartilage homeostasis. Free Radic Biol. Med. 132, 73\u201382. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2018.08.038 (2019).","journal-title":"Free Radic Biol. Med."},{"key":"89423_CR30","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1634\/theoncologist.2015-0446","volume":"21","author":"SK Saha","year":"2016","unstructured":"Saha, S. K., Zhu, A. X., Fuchs, C. S. & Brooks, G. A. Forty-year trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the rise. Oncologist 21, 594\u2013599. https:\/\/doi.org\/10.1634\/theoncologist.2015-0446 (2016).","journal-title":"Oncologist"},{"key":"89423_CR31","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3322\/caac.21759","volume":"73","author":"D Moris","year":"2023","unstructured":"Moris, D. et al. Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and future therapeutic landscape for clinicians. CA Cancer J. Clin. 73, 198\u2013222. https:\/\/doi.org\/10.3322\/caac.21759 (2023).","journal-title":"CA Cancer J. Clin."},{"key":"89423_CR32","doi-asserted-by":"publisher","first-page":"541","DOI":"10.6004\/jnccn.2021.0022","volume":"19","author":"AB Benson","year":"2021","unstructured":"Benson, A. B. et al. Hepatobiliary cancers, Version 2.2021, NCCN Clinical Practice guidelines in Oncology. J. Natl. Compr. Canc Netw. 19, 541\u2013565. https:\/\/doi.org\/10.6004\/jnccn.2021.0022 (2021).","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"89423_CR33","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1080\/1120009X.2021.1953887","volume":"34","author":"R Filippi","year":"2022","unstructured":"Filippi, R. et al. Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis. J. Chemother. 34, 123\u2013132. https:\/\/doi.org\/10.1080\/1120009X.2021.1953887 (2022).","journal-title":"J. Chemother."},{"key":"89423_CR34","doi-asserted-by":"publisher","unstructured":"Dong, B. et al. MiRNA-mediated EMT and CSCs in cancer chemoresistance. Exp. Hematol. Oncol. 10 https:\/\/doi.org\/10.1186\/s40164-021-00206-5 (2021).","DOI":"10.1186\/s40164-021-00206-5"},{"key":"89423_CR35","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1038\/s41467-021-21976-w","volume":"12","author":"B Zhang","year":"2021","unstructured":"Zhang, B. et al. Acetylation of KLF5 maintains EMT and tumorigenicity to cause chemoresistant bone metastasis in prostate cancer. Nat. Commun. 12, 1714. https:\/\/doi.org\/10.1038\/s41467-021-21976-w (2021).","journal-title":"Nat. Commun."},{"key":"89423_CR36","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.3892\/ijmm.2018.3399","volume":"41","author":"Y Lu","year":"2018","unstructured":"Lu, Y. et al. Effect of midkine on gemcitabine resistance in biliary tract cancer. Int. J. Mol. Med. 41, 2003\u20132011. https:\/\/doi.org\/10.3892\/ijmm.2018.3399 (2018).","journal-title":"Int. J. Mol. Med."},{"key":"89423_CR37","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1007\/s00534-011-0376-7","volume":"18","author":"J Sato","year":"2011","unstructured":"Sato, J. et al. Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma. J. Hepatobiliary Pancreat. Sci. 18, 700\u2013711. https:\/\/doi.org\/10.1007\/s00534-011-0376-7 (2011).","journal-title":"J. Hepatobiliary Pancreat. Sci."},{"key":"89423_CR38","doi-asserted-by":"publisher","first-page":"156","DOI":"10.3748\/wjg.v16.i2.156","volume":"16","author":"S Wolf","year":"2010","unstructured":"Wolf, S., Lorenz, J., M\u00f6ssner, J. & Wiedmann, M. Treatment of biliary tract cancer with NVP-AEW541: mechanisms of action and resistance. World J. Gastroenterol. 16, 156\u2013166 (2010).","journal-title":"World J. Gastroenterol."},{"key":"89423_CR39","doi-asserted-by":"publisher","first-page":"110676","DOI":"10.1016\/j.biopha.2020.110676","volume":"131","author":"D Xue","year":"2020","unstructured":"Xue, D., Zhou, X. & Qiu, J. Emerging role of NRF2 in ROS-mediated tumor chemoresistance. Biomed. Pharmacother. 131, 110676. https:\/\/doi.org\/10.1016\/j.biopha.2020.110676 (2020).","journal-title":"Biomed. Pharmacother"},{"key":"89423_CR40","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.1002\/jcb.23210","volume":"112","author":"V Pandey","year":"2011","unstructured":"Pandey, V., Chaube, B. & Bhat, M. K. Hyperglycemia regulates MDR-1, drug accumulation and ROS levels causing increased toxicity of carboplatin and 5-fluorouracil in MCF-7 cells. J. Cell. Biochem. 112, 2942\u20132952. https:\/\/doi.org\/10.1002\/jcb.23210 (2011).","journal-title":"J. Cell. Biochem."},{"key":"89423_CR41","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.3892\/or.2013.2771","volume":"30","author":"N Liu","year":"2013","unstructured":"Liu, N. et al. The BH3 mimetic S1 induces endoplasmic reticulum stress-associated apoptosis in cisplatin-resistant human ovarian cancer cells although it activates autophagy. Oncol. Rep. 30, 2677\u20132684. https:\/\/doi.org\/10.3892\/or.2013.2771 (2013).","journal-title":"Oncol. Rep."},{"key":"89423_CR42","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/j.bbrc.2015.07.093","volume":"464","author":"JS Park","year":"2015","unstructured":"Park, J. S., Kang, D. H. & Bae, S. H. p62 prevents carbonyl cyanide m-chlorophenyl hydrazine (CCCP)-induced apoptotic cell death by activating Nrf2. Biochem. Biophys. Res. Commun. 464, 1139\u20131144. https:\/\/doi.org\/10.1016\/j.bbrc.2015.07.093 (2015).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"89423_CR43","doi-asserted-by":"publisher","unstructured":"Lee, S., Rauch, J. & Kolch, W. Targeting MAPK signaling in Cancer: mechanisms of Drug Resistance and Sensitivity. Int. J. Mol. Sci. 21 https:\/\/doi.org\/10.3390\/ijms21031102 (2020).","DOI":"10.3390\/ijms21031102"},{"key":"89423_CR44","doi-asserted-by":"publisher","first-page":"19245","DOI":"10.1074\/jbc.M208134200","volume":"278","author":"A Mansouri","year":"2003","unstructured":"Mansouri, A. et al. Sustained activation of JNK\/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J. Biol. Chem. 278, 19245\u201319256 (2003).","journal-title":"J. Biol. Chem."},{"key":"89423_CR45","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/s41419-022-04833-6","volume":"13","author":"M Mao","year":"2022","unstructured":"Mao, M. et al. HJURP regulates cell proliferation and chemo-resistance via YAP1\/NDRG1 transcriptional axis in triple-negative breast cancer. Cell. Death Dis. 13, 396. https:\/\/doi.org\/10.1038\/s41419-022-04833-6 (2022).","journal-title":"Cell. Death Dis."},{"key":"89423_CR46","doi-asserted-by":"publisher","first-page":"738","DOI":"10.7150\/ijms.24981","volume":"15","author":"T Liu","year":"2018","unstructured":"Liu, T. et al. The suppression of DUSP5 expression correlates with paclitaxel resistance and poor prognosis in basal-like breast cancer. Int. J. Med. Sci. 15, 738\u2013747. https:\/\/doi.org\/10.7150\/ijms.24981 (2018).","journal-title":"Int. J. Med. Sci."},{"key":"89423_CR47","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1620\/tjem.2024.J041","volume":"264","author":"Y Lan","year":"2024","unstructured":"Lan, Y., Xu, H. & Jin, L. HJURP Derived from Cancer-Associated fibroblasts promotes glutamine metabolism to Induce Resistance to Doxorubicin in Ovarian Cancer. Tohoku J. Exp. Med. 264, 31\u201339. https:\/\/doi.org\/10.1620\/tjem.2024.J041 (2024).","journal-title":"Tohoku J. Exp. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89423-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89423-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89423-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T12:03:37Z","timestamp":1739102617000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89423-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,9]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["89423"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-89423-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4900217\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,9]]},"assertion":[{"value":"12 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4813"}}